LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Perspectives for immune plasma treatment of COVID-19

    Sayinalp, Başak / Çinar, Olgu Erkin / Haznedaroğlu, İbrahİm Celalettin

    Turkish journal of medical sciences

    2021  Volume 51, Issue 1, Page(s) 1–9

    MeSH term(s) Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/therapeutic use ; Antibodies, Viral/immunology ; Antibodies, Viral/therapeutic use ; COVID-19/therapy ; Humans ; Immunization, Passive/methods ; SARS-CoV-2/immunology
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral
    Keywords covid19
    Language English
    Publishing date 2021-02-26
    Publishing country Turkey
    Document type Journal Article ; Review
    ZDB-ID 1183461-4
    ISSN 1303-6165 ; 1300-0144
    ISSN (online) 1303-6165
    ISSN 1300-0144
    DOI 10.3906/sag-2005-410
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3242: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Iliac artery aneurysm in Behçet's syndrome: collaborative management is essential.

    Bilgin, Emre / Sayinalp, Basak / Eldem, Gonca / Karadag, Omer

    Rheumatology (Oxford, England)

    2021  Volume 60, Issue Suppl 3, Page(s) iii32–iii34

    MeSH term(s) Adult ; Behcet Syndrome/complications ; Humans ; Iliac Aneurysm/diagnostic imaging ; Iliac Aneurysm/etiology ; Iliac Aneurysm/therapy ; Male
    Language English
    Publishing date 2021-06-17
    Publishing country England
    Document type Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keab038
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 240: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 497: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Perspectives for the immune plasma treatment of COVID-19

    Sayinalp, BaSak / Çinar, Olgu ErkIn / HaznedaroGlu, IbrahIm CelalettIn

    Abstract: INTRODUCTION AND AIM: SARS-CoV-2 infection was declared as a pandemic by World Health Organization (WHO) on March 11, 2020, and the death toll from COVID-19, which is the disease caused by SARS-CoV-2, has already passed those of many previous epidemics. ... ...

    Abstract INTRODUCTION AND AIM: SARS-CoV-2 infection was declared as a pandemic by World Health Organization (WHO) on March 11, 2020, and the death toll from COVID-19, which is the disease caused by SARS-CoV-2, has already passed those of many previous epidemics. A wide variety of treatment options are being considered for COVID-19, but there is still no definitive treatment or vaccine. This review aims to explain the background of the convalescent plasma treatment and its relations with COVID-19 immunity, to define the ideal treatment procedures and to reveal present and future perspectives in the light of rapidly growing data. Immunological basis of COVID-19 associated immune response and convalescent plasma as a treatment option: Since it has been shown that the impaired immune response of the host is one of the most important factors that increase the severity of the infection, treatment strategies to suppress aberrant immune activation are being dwelled on. Convalescent/immune plasma, which is derived from recently recovered patients and contains neutralizing antibodies and many other immune-modulatory substances, seems to be the most convenient strategy to restore normal immune function considering the fast-spreading nature of the ongoing pandemic. Conclusion and future perspectives: Even though mechanisms of action of plasma therapy are not fully delineated, it has been shown that it could lead to a reduction in mortality since other alternatives such as monoclonal antibodies or SARS-CoV-2 hyper immunoglobulin require much more time and effort to be developed.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #689057
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Evaluation of early unplanned readmissions and predisposing factors in an oncology clinic.

    Guven, Deniz Can / Ceylan, Furkan / Cakir, Ibrahim Yahya / Cesmeci, Engin / Sayinalp, Basak / Yesilyurt, Berkay / Guner, Gurkan / Yildirim, Hasan Cagri / Aktepe, Oktay Halit / Arik, Zafer / Turker, Alev / Dizdar, Omer

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

    2021  Volume 29, Issue 7, Page(s) 4159–4164

    Abstract: Background: Unplanned readmission in the first 30 days after discharge is an important medical problem, although the data on cancer patients is limited. So we planned to evaluate the rates and causes of early readmissions and the predisposing factors.!## ...

    Abstract Background: Unplanned readmission in the first 30 days after discharge is an important medical problem, although the data on cancer patients is limited. So we planned to evaluate the rates and causes of early readmissions and the predisposing factors.
    Methods: Patients hospitalized in Hacettepe University Oncology services between August 2018 and July 2019 were included. The demographic features, tumor stages, regular drugs, last laboratory parameters before discharge, and readmissions in the first 30 days after discharge were recorded. The predisposing features were evaluated with univariate and multivariate analyses.
    Results: A total of 562 hospitalizations were included. The mean age of the patients was 58.5 ± 14.5 years. Almost 2/3 of the hospitalizations were due to symptom palliation and infections. Eighty-three percent of the patients had advanced disease, and over 60% had an ECOG score of 2 and above. In the first 30 days after discharge, 127 patients were readmitted (22.6%). Advanced stage disease, presence of polypharmacy (5 or more regular drugs), hospitalization setting (emergency department (ED) vs. outpatient clinic), and hypoalbuminemia (< 3 gr/dL) were associated with a statistically significant increase in the risk of readmission. Among these factors, advanced-stage disease (HR: 2.847, 95% CI: 1.375-5.895), hospitalization from ED (HR: 1.832, 95% CI: 1.208-2.777), and polypharmacy (HR: 1.782, 95% CI: 1.173-2.706) remained significant in multivariate analyses.
    Conclusions: In this study, 22% of cancer patients had early readmissions. The readmission risk increased in patients with advanced disease, hospitalization from ED, and polypharmacy. The optimal post-discharge plan may reduce readmissions in all oncology patients, with priority for these patient groups.
    MeSH term(s) Adult ; Aftercare ; Aged ; Aged, 80 and over ; Ambulatory Care Facilities ; Causality ; Emergency Service, Hospital/statistics & numerical data ; Hospitalization/statistics & numerical data ; Humans ; Hypoalbuminemia/blood ; Male ; Middle Aged ; Neoplasms/pathology ; Neoplasms/therapy ; Patient Discharge ; Patient Readmission/statistics & numerical data ; Polypharmacy ; Retrospective Studies ; Risk Factors
    Language English
    Publishing date 2021-01-06
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1134446-5
    ISSN 1433-7339 ; 0941-4355
    ISSN (online) 1433-7339
    ISSN 0941-4355
    DOI 10.1007/s00520-020-05927-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3697: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.

    Çınar, Olgu Erkin / Sayınalp, Başak / Aladağ Karakulak, Elifcan / Avşar Karataş, Ayşe / Velet, Mustafa / İnkaya, Ahmet Çağkan / Ersoy Ortaç, Nazmiye Ebru / Öcal, Serpil / Aksu, Salih / Haznedaroğlu, İbrahim Celalettin / Sayınalp, Nilgün / Özcebe, Osman İlhami

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

    2020  Volume 59, Issue 5, Page(s) 102821

    Abstract: During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with ... ...

    Abstract During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with associated comorbidities. Convalescent immune plasma therapy is a promising option as a sort of 'rescue' treatment in COVID-19 immune syndrome, where miraculous antiviral drugs are not available yet. In this report, we aim to convey our experience of multi-task treatment approach with convalescent immune plasma and anti-cytokine drug combination in a COVID-19 patient with extremely challenging comorbidities including active myeloid malignancy, disseminated tuberculosis and kidney failure.
    MeSH term(s) Body Temperature ; COVID-19/complications ; COVID-19/diagnostic imaging ; COVID-19/immunology ; COVID-19/therapy ; Humans ; Immunization, Passive ; Lymphocyte Count ; Male ; Middle Aged ; Myelodysplastic Syndromes/complications ; Myelodysplastic Syndromes/diagnostic imaging ; Myelodysplastic Syndromes/virology ; SARS-CoV-2/physiology ; Tomography, X-Ray Computed ; Tuberculosis/complications ; Tuberculosis/diagnostic imaging ; Tuberculosis/virology
    Keywords covid19
    Language English
    Publishing date 2020-05-29
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2046795-3
    ISSN 1878-1683 ; 1473-0502
    ISSN (online) 1878-1683
    ISSN 1473-0502
    DOI 10.1016/j.transci.2020.102821
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis

    Çinar, Olgu Erkin / Sayinalp, Basak / Aladag Karakulak, Elifcan / Avsar Karatas, Ayse / Velet, Mustafa / Inkaya, Ahmet Çagkan / Ersoy Ortaç, Nazmiye Ebru / Öcal, Serpil / Aksu, Salih / Haznedaroglu, Ibrahim Celalettin / Sayinalp, Nilgün / Özcebe, Osman Ilhami

    Transfus Apher Sci

    Abstract: During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with ... ...

    Abstract During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with associated comorbidities. Convalescent immune plasma therapy is a promising option as a sort of 'rescue' treatment in COVID-19 immune syndrome, where miraculous antiviral drugs are not available yet. In this report, we aim to convey our experience of multi-task treatment approach with convalescent immune plasma and anti-cytokine drug combination in a COVID-19 patient with extremely challenging comorbidities including active myeloid malignancy, disseminated tuberculosis and kidney failure.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #437255
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis

    Çınar, Olgu Erkin / Sayınalp, Başak / Aladağ Karakulak, Elifcan / Avşar Karataş, Ayşe / Velet, Mustafa / İnkaya, Ahmet Çağkan / Ersoy Ortaç, Nazmiye Ebru / Öcal, Serpil / Aksu, Salih / Haznedaroğlu, İbrahim Celalettin / Sayınalp, Nilgün / Özcebe, Osman İlhami

    Transfusion and Apheresis Science

    2020  , Page(s) 102821

    Keywords Hematology ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2046795-3
    ISSN 1878-1683 ; 1473-0502
    ISSN (online) 1878-1683
    ISSN 1473-0502
    DOI 10.1016/j.transci.2020.102821
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top